Combination therapeutic drug comprising anti-HER2 bispecific antibody and use thereof

The combination of anti-HER2 bispecific antibodies and docetaxel albumin compositions is used to form docetaxel albumin nanoparticle compositions, which solves the cumbersome and therapeutic effects of the existing HER2-positive breast cancer recurrence and metastatic treatment. The problem of insufficient achieves more efficient and safer treatment effects.

CN119055767APending Publication Date: 2024-12-03SHANGHAI JMT BIO TECHNOLOGY CO LTD +1
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410566817.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-09
Filing Date
2024-05-09
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

In the existing recurrence and metastatic treatment plans for HER2-positive breast cancer, the administration of trastuzumab combined with pertuzumab and docetaxel is complicated and inconvenient, resulting in long treatment stays in patients, increasing the risk of in-hospital infection and Medical resources are occupied and some patients are resistant to existing treatment plans, so there is a problem of insufficient treatment options.

Method used

Docetaxel albumin nanoparticles are formed by combining the bispecific antibodies targeting different epitopes of HER2 protein and docetaxel albumin. Compositions for the treatment of HER2-positive recurrent metastatic breast cancer, simplifying the administration process and improving efficacy.

Benefits of technology

In clinical studies, the composition has shown better anti-tumor efficacy than the existing standard treatment regimen. It has good overall safety and convenient administration, providing a first-line treatment with better efficacy, good safety and more convenient treatment. choose.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055767A_ABST
    Figure CN119055767A_ABST
Patent Text Reader

Abstract

The invention relates to the field of biological pharmacy, in particular to a combined therapeutic drug containing an anti-HER2 bispecific antibody and application of the combined therapeutic drug, in particular to application of an anti-HER2 bispecific antibody combined docetaxel albumin composition in preparation of drugs for treating advanced malignant solid tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biopharmaceuticals, and more specifically, to a combined therapeutic drug comprising an anti-HER2 bispecific antibody and uses thereof, in particular to use of an anti-HER2 bispecific antibody combined with docetaxel albumin composition in the preparation of a drug for treating advanced malignant solid tumors. Background Art

[0002] The latest data released by the International Agency for Research on Cancer show that in 2020, there were 2.26 million new cases of breast cancer worldwide, replacing lung cancer as the world's number one new cancer, and 684,000 deaths, making it the leading cause of cancer death among women. Among them, there were 416,000 new cases of breast cancer in my country, accounting for 18.4% of new cases worldwide, and 117,000 deaths, accounting for 17.1% of global breast cancer deaths. The trend is increasing year by year, seriously threatening the lives and health of Chinese women, and has become one of the priorities of cancer prevention and treatment in my country.

[0003] Breast cancer is divided into different histopathological subtypes according to the expression of estrogen receptor / progesterone receptor and human epidermal growth factor receptor 2 (HER2). Among them, HER2-positive accounts for about 15-20% of all breast cancers. Compared with Western countries, the proportion of HER2-positive breast cancer in China is higher, at 20-30%. HER2-positive is a subtype of breast cancer with higher malignancy and younger onset population. Compared with hormone receptor-positive / HER2-negative and triple-negative breast cancer, HER2-positive breast cancer has a higher proportion of patients with stage III-IV at the time of initial diagnosis, a higher degree of histological grade, and most of them are under 65 years old at the time of initial diagnosis. At present, the drugs approved for the treatment of HER2-positive breast cancer in my country include trastuzumab, pertuzumab, lapatinib, neratinib, pyrotinib and emtansine trastuzumab (T-DM1). The above drugs run through the entire treatment of HER2-positive breast cancer, including neoadjuvant therapy, postoperative adjuvant therapy and systemic treatment of recurrence and metastasis. Despite this, palliative salvage therapy is still the main purpose of treatment for recurrent and metastatic breast cancer, and further improvement is needed.

[0004] In China, about 20% of patients have advanced breast cancer (stage III / IV) at the time of initial diagnosis. In addition, about 10% of HER2-positive early subjects will experience disease recurrence 3 years after radical surgery. Although first-line treatment with trastuzumab combined with pertuzumab and docetaxel can significantly improve PFS and OS in patients with HER2-positive metastatic breast cancer. However, most subjects will still experience disease progression after treatment, and new and more effective treatment options are still needed. In addition, the trastuzumab combined with pertuzumab and docetaxel regimen requires periodic administration until disease progression or intolerance, and each cycle (3 weeks) requires intravenous infusion of pertuzumab for 30 to 60 minutes (loading dose requires intravenous infusion for 60 minutes), and trastuzumab requires infusion for 30 to 90 minutes (loading dose requires intravenous infusion for 90 minutes), and it is recommended to observe for 30 to 60 minutes between the administration of the two. Long-term repeated intravenous infusion treatment is inconvenient, and patients stay in the hospital for a long time, which increases the risk of nosocomial infection. At the same time, there are more medical resource occupation problems that need to be further resolved. In summary, HER2-positive breast cancer urgently needs a more effective, safe and convenient first-line treatment option.

[0005] Docetaxel is a semi-synthesized product of a non-cytotoxic precursor (10-deacetylbaccatin III) extracted from the needles of Taxus chinensis. It is a paclitaxel analogue and has stronger anti-tumor activity than paclitaxel. Docetaxel is poorly water-soluble. The current commercially available preparation is its ordinary injection, which was first developed by Sanofi and is traded under the name TAXOTERE. The usual dosage is 75 mg / m2 once every 3 weeks as a 1-hour intravenous infusion. 2 However, Docetaxel injection, represented by FDA, may cause severe allergic reactions due to the use of ethanol and Tween 80 in the formula, requiring dexamethasone pretreatment and poor patient compliance. In addition, ethanol can affect the central nervous system, requiring a lower infusion rate to alleviate poisoning symptoms. Summary of the invention

[0006] In view of the deficiencies of the prior art, the present invention provides a combination drug for treating cancer, which is combined with an anti-HER2 bispecific antibody and docetaxel albumin composition for the treatment of HER2-positive recurrent metastatic breast cancer. It has better anti-tumor efficacy than existing standard treatment regimens, and has good overall safety and more convenient administration. It can provide such patients with a first-line treatment option with better efficacy, good safety and more convenient treatment.

[0007] In a first aspect, the present invention provides a use of an anti-HER2 antibody and a second therapeutic agent in the preparation of a medicament for treating cancer, wherein the second therapeutic agent is a docetaxel albumin composition.

[0008] In a second aspect, the present invention provides a use of an anti-HER2 antibody in the preparation of a medicament for enhancing the efficacy of a second therapeutic agent in treating cancer, wherein the second therapeutic agent is a docetaxel albumin composition.

[0009] In a third aspect, the present invention provides a method for treating cancer using an anti-HER2 antibody and a second therapeutic agent, wherein the second therapeutic agent is a docetaxel albumin composition.

[0010] In a fourth aspect, the present invention provides a pharmaceutical composition or a kit or a medicine box for treating cancer, comprising an anti-HER2 antibody and a second therapeutic agent, wherein the second therapeutic agent is a docetaxel albumin composition.

[0011] All of the above:

[0012] In some embodiments, the combination of the anti-HER2 antibody and the second therapeutic agent is synergistic in treating cancer.

[0013] In some embodiments, the anti-HER2 antibody is an anti-HER2 bispecific antibody.

[0014] In some embodiments, the anti-HER2 antibody is a bispecific antibody targeting different epitopes of human HER2 protein.

[0015] In some embodiments, the anti-HER2 antibody is a bispecific antibody targeting different epitopes of human HER2 protein, wherein the different epitopes of HER2 protein are domain II and domain IV thereof.

[0016] In some embodiments, the anti-HER2 antibody is a recombinant humanized antibody. In some embodiments, the anti-HER2 antibody comprises two common light chains with the same sequence. In some embodiments, the common light chain comprises CDR-L1 as shown in SEQ ID NO: 1, CDR-L2 as shown in SEQ ID NO: 2, and CDR-L3 as shown in SEQ ID NO: 3. In some embodiments, the common light chain comprises a light chain variable region as shown in SEQ ID NO: 4 or its light chain variable region consists of the amino acid sequence shown in SEQ ID NO: 4. In some embodiments, the common light chain comprises or consists of the amino acid sequence shown in SEQ ID NO: 5.

[0017] In some embodiments, the common light chain of the anti-HER2 antibodies is of the Kappa subtype.

[0018] In some embodiments, the anti-HER2 antibody comprises two heavy chains with different sequences. In some embodiments, the heavy chain comprises a heavy chain I targeting the HER2 protein domain II. In some embodiments, the heavy chain I comprises CDR-H1-1 as shown in SEQ ID NO:6, CDR-H1-2 as shown in SEQ ID NO:7, and CDR-H1-3 as shown in SEQ ID NO:8. In some embodiments, the heavy chain I comprises a heavy chain I variable region as shown in SEQ ID NO:9 or a heavy chain I variable region consisting of an amino acid sequence as shown in SEQ ID NO:9. In some embodiments, the heavy chain I comprises or consists of an amino acid sequence as shown in SEQ ID NO:10 or SEQ ID NO:16.

[0019] In some embodiments, the anti-HER2 antibody comprises two heavy chains with different sequences. In some embodiments, the heavy chain comprises a heavy chain II targeting the HER2 protein domain IV. In some embodiments, the heavy chain II comprises a CDR-H2-1 as shown in SEQ ID NO: 11, a CDR-H2-2 as shown in SEQ ID NO: 12, and a CDR-H2-3 as shown in SEQ ID NO: 13. In some embodiments, the heavy chain II comprises a heavy chain II variable region as shown in SEQ ID NO: 14 or a heavy chain II variable region consisting of an amino acid sequence as shown in SEQ ID NO: 14. In some embodiments, the heavy chain II comprises or consists of an amino acid sequence as shown in SEQ ID NO: 15 or SEQ ID NO: 17.

[0020] In some embodiments, the heavy chain comprises heavy chain I targeting HER2 protein domain II and heavy chain II targeting HER2 protein domain IV, wherein heavy chain I and heavy chain II are as described above.

[0021] In some embodiments, the anti-HER2 antibody is KN026 of Jiangsu Alphamab Oncology Biopharmaceuticals Co., Ltd. (hereinafter referred to as KN026).

[0022] In some embodiments, the cancer includes but is not limited to a hematological tumor or a solid tumor.

[0023] In some embodiments, the cancer is a hematologic tumor. In some embodiments, the cancer is a lymphoma or leukemia. In some embodiments, the lymphoma or leukemia includes but is not limited to myeloma, B-cell lymphoma, mantle cell lymphoma, non-Hodgkin's B-cell lymphoma, non-Hodgkin's T-cell lymphoma, cutaneous lymphoma, anaplastic large cell lymphoma, multiple myeloma, inert non-Hodgkin's lymphoma, plasma cell tumor, chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma. In some embodiments, the above cancer is relapsed or refractory.

[0024] In some embodiments, the cancer is a solid tumor. In some embodiments, the solid tumor includes but is not limited to bladder cancer, brain cancer, breast cancer, cervical cancer, chest tumor, endometrial cancer, esophageal squamous cell carcinoma, gastric cancer, head tumor, pancreatic cancer, bile duct cancer, colorectal cancer, eye cancer, head and neck squamous cell carcinoma, urothelial carcinoma, kidney cancer, liver cancer, lymph node cancer, lung cancer, oral cancer, neck tumor, ovarian cancer, prostate cancer, testicular cancer, laryngeal cancer and uterine cancer, melanoma, skin cancer, salivary gland cancer, soft tissue sarcoma and osteosarcoma. In some embodiments, the above cancer is recurrent or refractory.

[0025] In some embodiments, the cancer is selected from breast cancer.

[0026] In some embodiments, the breast cancer is HER2-positive breast cancer, preferably HER2-positive breast cancer with IHC3+ or HER2-positive breast cancer with IHC2+ and ISH-positive. In some embodiments, the breast cancer is selected from hormone receptor-positive or -negative HER2-positive breast cancer, preferably HER2-positive breast cancer with negative estrogen receptor and progesterone receptor, HER2-positive breast cancer with positive estrogen receptor and / or progesterone receptor.

[0027] In some embodiments, the breast cancer includes: ductal carcinoma, lobular carcinoma, medullary carcinoma, glial carcinoma, tubular carcinoma, inflammatory breast cancer, triple negative breast cancer (TNBC).

[0028] In some embodiments, the breast cancer is recurrent or metastatic breast cancer. In some embodiments, the breast cancer is selected from breast cancer with visceral metastasis or breast cancer without visceral metastasis.

[0029] In some embodiments, the breast cancer is recurrent and metastatic breast cancer.

[0030] In some embodiments, the breast cancer is recurrent or metastatic breast cancer that has not previously received systemic chemotherapy and / or HER2-targeted therapy for recurrent or metastatic breast cancer, or breast cancer that relapsed more than 12 months after the end of neoadjuvant therapy or adjuvant therapy or HER2-targeted therapy. The systemic chemotherapy is selected from taxane chemotherapy drugs such as docetaxel, albumin-paclitaxel, capecitabine, vinorelbine, etc.; the HER2 targeted therapy is selected from trastuzumab, pertuzumab, pyrotinib, trastuzumab-emtansine conjugate (TDM-1); the neoadjuvant therapy is selected from: trastuzumab, taxanes and pertuzumab with or without carboplatin; anthracyclines combined with cyclophosphamide and taxanes, trastuzumab, pertuzumab; the adjuvant therapy is selected from: anthracyclines combined with cyclophosphamide sequentially with taxanes combined with trastuzumab and pertuzumab; docetaxel combined with carboplatin combined with trastuzumab and pertuzumab; trastuzumab / pertuzumab sequentially with neratinib; TDM-1.

[0031] In some embodiments, the anti-HER2 antibody and the second therapeutic agent are the only therapeutically active ingredients.

[0032] In some embodiments, the uses, methods, pharmaceutical compositions, or kits described herein further comprise a third therapeutic agent, which is a chemotherapeutic agent. The chemotherapeutic agent is, for example, bendamustine, chlorambucil, cyclophosphamide, doxorubicin, vincristine, fludarabine, carboplatin, cisplatin, or any combination thereof.

[0033] In some embodiments, the uses, methods, pharmaceutical compositions, or kits or kits described herein further comprise drugs to support treatment, such as granulocyte colony stimulating factor (G-CSF).

[0034] In some embodiments, the anti-HER2 antibody and the second therapeutic agent are contained in the same dosage unit.

[0035] In some embodiments, the anti-HER2 antibody and the second therapeutic agent are each contained in a separate formulation unit.

[0036] In some embodiments, the drug, pharmaceutical composition, kit or drug kit described in the present application is administered to a patient or subject in need in a clinically acceptable manner, preferably by intravenous infusion. Accordingly, the anti-HER2 antibody and the second therapeutic agent are clinically acceptable preparations, preferably in the form of injections, including liquid injections, powders for injection, and tablets for injection.

[0037] In some embodiments, the anti-HER2 antibody is formulated into a preparation, and the content of the anti-HER2 antibody or a pharmaceutically acceptable form thereof (based on the anhydrous amount of the anti-HER2 antibody) in each preparation unit is in the range of about 0.01 mg to about 400 mg, preferably about 300-400 mg, more preferably about 300 mg, about 325 mg, about 350 mg, about 375 mg, or about 400 mg.

[0038] In some embodiments, the anti-HER2 antibody is administered at a dose of about 0.01 mg / kg-100 mg / kg, preferably about 20-40 mg / kg, about 20 mg / kg-30 mg / kg, about 25 mg / kg-35 mg / kg, and more preferably about 30 mg / kg.

[0039] In some embodiments, the anti-HER2 antibody is administered in one or more dosing cycles (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 or more dosing cycles). Preferably, it is administered in three or more dosing cycles. In some embodiments of the present invention, the dosing cycle of the anti-HER2 antibody continues until the clinical benefit is lost (e.g., confirmed as disease progression, drug resistance, death or unacceptable toxicity).

[0040] In some embodiments, the docetaxel albumin composition is formulated into a preparation, wherein each preparation unit contains 50-100 mg, preferably 70-90 mg, and more preferably about 80 mg, of docetaxel (calculated as anhydrous docetaxel).

[0041] In some embodiments, preferably, the docetaxel albumin composition is a powder for injection, which contains about 50-100 mg / vial of active ingredient, preferably about 70-90 mg / vial, and more preferably about 80 mg / vial, calculated as anhydrous docetaxel.

[0042] In some embodiments, the docetaxel albumin composition is administered at a dose of about 60-125 mg / m 2 , preferably about 60-100 mg / m 2 , more preferably about 60 mg / m 2 , about 75mg / m 2 or about 100 mg / m 2 .

[0043] In some embodiments, the docetaxel albumin composition is administered in one or more dosing cycles (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 or more dosing cycles). Preferably, it is administered in three or more dosing cycles. In some embodiments of the present invention, the docetaxel albumin composition is administered until the clinical benefit is lost (e.g., confirmed as disease progression, drug resistance, death or unacceptable toxicity).

[0044] In some embodiments of the invention, the length of each cycle in one or more dosing cycles is 14 days. In some embodiments of the invention, the length of each cycle in one or more dosing cycles is 21 days. In some embodiments of the invention, the length of each cycle in one or more dosing cycles is 28 days. Preferably, the length of each cycle in one or more dosing cycles is 21 days.

[0045] In some embodiments of the present invention, the anti-HER2 antibody and / or docetaxel albumin combination is administered at a frequency of QW (once a week), Q2W (once every two weeks), Q3W (once every three weeks) or Q4W (once every four weeks).

[0046] In some embodiments of the present invention, the anti-HER2 antibody and / or docetaxel albumin composition is administered once every 3 weeks (Q3W), with 21 days as one treatment cycle.

[0047] In some embodiments of the present invention, the anti-HER2 antibody and / or docetaxel albumin composition is administered once every 4 weeks (Q4W), with 28 days as one treatment cycle.

[0048] In some embodiments of the present invention, the anti-HER2 antibody and / or docetaxel albumin composition is administered once every 2 weeks (Q2W), with 14 days or 28 days as one treatment cycle.

[0049] In some embodiments of the present invention, the anti-HER2 antibody and / or docetaxel albumin composition is administered once a week (QW) for 3 consecutive weeks, followed by one week of rest, with 28 days as one treatment cycle.

[0050] In some embodiments of the present invention, the anti-HER2 antibody and / or docetaxel albumin composition is administered once a week (QW) for 2 consecutive weeks, followed by a one-week break, with 21 days as one treatment cycle.

[0051] In some embodiments of the present invention, the anti-HER2 antibody and / or docetaxel albumin composition is administered on about day 1 (eg, day 1, 2, 3, or 4) of each dosing cycle.

[0052] In some embodiments of the present invention, the anti-HER2 antibody is administered before or after the docetaxel albumin composition.

[0053] The drug, pharmaceutical composition, kit or drug box described in the present application is administered to a patient or subject in need in a therapeutically effective amount for treating breast cancer. The breast cancer is as described above.

[0054] In some embodiments, the medicament, pharmaceutical composition, kit or drug box of the present application comprises an anti-HER2 antibody and a docetaxel albumin composition, which is administered to a patient or subject in need thereof in a therapeutically effective amount for the treatment of breast cancer, wherein the breast cancer is as described above.

[0055] In some embodiments, the anti-HER2 antibody is administered once every 2-4 weeks, preferably once every 3 weeks; it is administered on the first day of each cycle, with a dose of about 20-40 mg / kg, preferably about 25-35 mg / kg, and more preferably about 30 mg / kg; the first intravenous drip is 90 min ± 15 min, and the subsequent cycles are intravenously dripped for 60 min ± 15 min. In some embodiments, the docetaxel albumin composition is administered once every 2-4 weeks, preferably once every 3 weeks; it is administered on the first day of each cycle, with a dose of about 60-125 mg / m 2 , preferably about 60-100 mg / m 2 , for example, about 60 mg / m 2 , about 75mg / m 2 or about 100 mg / m 2 , intravenous drip for 60min±10min.

[0056] In some embodiments, the anti-HER2 antibody is administered once every 3 weeks, on the first day of each cycle, at a dose of about 30 mg / kg, with the first intravenous drip for 90 min ± 15 min, and the subsequent cycles are intravenously dripped for 60 min ± 15 min. In some embodiments, the docetaxel albumin composition is administered once every 3 weeks, on the first day of each cycle, at a dose of about 60 mg / m 2 , about 75mg / m 2 or about 100 mg / m 2 , intravenous drip for 60min±10min.

[0057] In some embodiments, the docetaxel albumin composition described in the present application is prepared with reference to the method disclosed in WO2022184164A1. Studies have shown that both the suspension before lyophilization and the reconstituted suspension after lyophilization can be stable for at least 24 hours at room temperature and for at least 10 days under refrigerated conditions without turbidity of the suspension or precipitation of nanoparticles. Compared with the situation that the reconstituted suspension of commercially available albumin-bound drugs is only stable for 8 hours, this product greatly reduces the restrictions on clinical use.

[0058] The docetaxel albumin composition described in the present application is a docetaxel albumin nanoparticle composition, comprising docetaxel and acid-denatured albumin, and optionally comprising an osmotic pressure regulator and / or a pH regulator. The acid-denatured albumin is obtained by denaturing human albumin by adding acid to adjust to an appropriate pH value. Preferably:

[0059] (1) The acid is selected from acidic amino acids or acidic polypeptides, organic acids, and inorganic acids. The acidic amino acids or acidic polypeptides include but are not limited to cysteine ​​hydrochloride, glutathione, etc.; the organic acids include but are not limited to citric acid, tartaric acid, etc.; the inorganic acids include but are not limited to hydrochloric acid, sulfuric acid, etc. The acid is preferably cysteine ​​hydrochloride, glutathione, hydrochloric acid, and more preferably cysteine ​​hydrochloride; and / or

[0060] (2) the appropriate pH value is preferably about 3.5 to 5.5, preferably about 3.5 to 5.0, more preferably about 3.8 to 4.7, more preferably about 4.0 to 4.5; and / or

[0061] (3) based on anhydrous docetaxel, the mass ratio of docetaxel to human albumin is 1:(2.0-10.0), preferably 1:(3.0-7.0), more preferably 1:(4.0-6.0); most preferably, about 1:4.5; and / or

[0062] (4) The content of sodium octanoate in the human serum albumin is not higher than 0.08 mmol / g protein, preferably 0.03-0.08 mmol / g protein, further preferably 0.04-0.08 mmol / g protein, and more preferably 0.04-0.07 mmol / g protein.

[0063] In some embodiments, the particle size of the docetaxel albumin nanoparticles is about 60-200 nm, preferably about 90-150 nm, and more preferably about 90-135 nm.

[0064] The type of the osmotic pressure regulator is not particularly limited, for example, it can be selected from sodium chloride, glucose, phosphate or citrate, etc., preferably sodium chloride. In some embodiments, the osmotic pressure regulator is sodium chloride, and the weight ratio of sodium chloride to docetaxel is (0.75-9):1, preferably (1-7):1, preferably (1.5-4.5):1, and most preferably about 2.25:1.

[0065] The type of the pH adjuster is not particularly limited, and is used to adjust the pH value within an appropriate range. Preferably, the pH value range is 3.4-5.8; preferably 3.6-5.6, or 3.8-5.0, more preferably 3.9-4.8, and most preferably about 4.1.

[0066] The docetaxel albumin composition described in the present application has no special requirements on whether the docetaxel is in the form of a hydrate, and can be selected from any one of anhydrous docetaxel, docetaxel hemihydrate or docetaxel trihydrate; preferably, the docetaxel is selected from anhydrous docetaxel. The content of docetaxel described in the present application is calculated based on anhydrous docetaxel.

[0067] The drug described in the present application comprises a docetaxel albumin composition. The drug is a clinically acceptable dosage form, preferably an injection, and more preferably a liquid injection or a lyophilized powder injection. For example, the docetaxel for injection (albumin-bound) used in the specific embodiment is also called DTX-HSA.

[0068] In some embodiments, the drug is a liquid injection, and the pH value of the liquid injection is 3.4-5.8, preferably 3.6-5.6, or 3.8-5.0, more preferably 3.9-4.8. The particle size of docetaxel albumin nanoparticles in the liquid injection is about 60-200nm, preferably about 90-150nm, more preferably about 90-135nm; the liquid injection contains sodium chloride 0-1.8% (w / v), preferably 0.45%-1.8% (w / v), more preferably 0.9%-1.8% (w / v), more preferably 0.9% (w / v). In some embodiments, the liquid injection contains docetaxel 2-10mg / ml, preferably 2-8mg / ml.

[0069] In some embodiments, the drug is a lyophilized powder injection, the lyophilized powder injection contains sodium chloride, and the weight ratio of sodium chloride:docetaxel is (0.75-9):1, preferably (1-7):1; preferably (1.5-4.5):1, and most preferably about 2.25:1. The particle size of docetaxel albumin nanoparticles is about 60-200nm, preferably about 90-150nm, and more preferably about 90-135nm. The pH of the suspension for preparing the lyophilized powder injection before lyophilization is 3.4-5.8, preferably 3.6-5.6, or 3.8-5.0, more preferably 3.9-4.8, and most preferably about 4.1.

[0070] The lyophilized powder injection is reconstituted with a reconstitution medium before use. The reconstitution medium is selected from water for injection, sodium chloride solution or glucose solution, preferably water for injection. The pH value of the reconstituted suspension obtained is 3.4-5.8, preferably 3.6-5.6, or 3.8-5.0, more preferably 3.9-4.8. The particle size of docetaxel albumin nanoparticles in the reconstituted suspension is about 60-200nm, preferably about 90-150nm, more preferably about 90-135nm. The reconstituted suspension contains 0-1.8% (w / v) sodium chloride, preferably 0.45%-1.8% (w / v), more preferably 0.9%-1.8% (w / v), more preferably 0.9%. In some embodiments, the reconstituted suspension contains docetaxel 2-10mg / ml, preferably 2-8mg / ml.

[0071] The preparation method of the docetaxel albumin composition described in the present application comprises the following steps:

[0072] (1) dissolving docetaxel in an organic solvent to obtain an organic phase solution;

[0073] (2) taking a human albumin solution, adding acid to adjust the pH value, and obtaining an acid-denatured albumin aqueous solution; and taking another salt solution;

[0074] (3) mixing the organic phase solution, the aqueous phase solution and the salt solution to carry the drug to obtain a drug-loaded solution;

[0075] (4) Dialysis to obtain a dialyzed suspension.

[0076] Wherein, before adding acid to adjust the pH value, step (2) optionally comprises the step of diluting the human albumin solution with water for injection to obtain an albumin dilution solution.

[0077] Wherein, step (2) optionally comprises an incubation step after adding acid to adjust the pH value.

[0078] Wherein, step (3) optionally comprises a cooling step after mixing the drug-loaded materials.

[0079] Wherein, step (4) optionally comprises, before dialysis, concentrating the drug-loaded solution obtained in step (3) to obtain a concentrated solution.

[0080] Wherein, after dialysis, step (4) optionally comprises a concentration or dilution step to adjust the concentration of docetaxel in the suspension after dialysis.

[0081] Wherein, step (4) optionally includes step (5) of sterilization filtration.

[0082] Wherein, step (5) optionally comprises step (6) of freeze-drying.

[0083] Wherein, the docetaxel in step (1) is in any form, preferably anhydrous docetaxel, docetaxel hemihydrate or docetaxel trihydrate. Based on anhydrous docetaxel, the mass ratio of docetaxel to human albumin is 1:(2.0-10.0), preferably 1:(3.0-7.0), more preferably 1:(4.0-6.0), and most preferably about 1:4.5).

[0084] Wherein, the organic solvent in step (1) is selected from solvents miscible with water, such as ethanol, methanol, acetone, DMSO, etc., preferably ethanol. Based on anhydrous docetaxel, the organic phase solution contains 45-90 mg / ml of docetaxel, preferably 45-70 mg / ml.

[0085] Wherein, the content of sodium octanoate in the human albumin solution in step (2) is not higher than 0.12 mmol / g protein, preferably not higher than 0.08 mmol / g protein, preferably 0.045-0.08 mmol / g protein.

[0086] Wherein, in step (2), the albumin diluent contains 6-25 mg / ml of albumin, preferably 10-20 mg / ml, more preferably 12-18 mg / ml, and more preferably about 15 mg / ml.

[0087] Wherein, in step (2), the acid is selected from acidic amino acids or acidic polypeptides, organic acids, and inorganic acids. The acidic amino acids or acidic polypeptides include but are not limited to cysteine ​​hydrochloride, glutathione, etc.; the organic acids include but are not limited to citric acid, tartaric acid, etc.; the inorganic acids include but are not limited to hydrochloric acid, sulfuric acid, etc. The acid is preferably cysteine ​​hydrochloride, glutathione, hydrochloric acid, and more preferably cysteine ​​hydrochloride. The pH value is preferably 3.5-5.5, preferably 3.5-5.0, more preferably 3.8-4.7, more preferably 4.0-4.5, and most preferably about 4.1.

[0088] Wherein, in step (2), the incubation refers to heating to 35°C-42°C, preferably 38°C-42°C, after adding acid to adjust the pH value; incubating for more than 30 minutes, preferably 30 minutes-60 minutes.

[0089] The salt solution in step (2) is selected from an aqueous solution of sodium chloride, potassium chloride, sodium sulfate or magnesium sulfate, preferably an aqueous solution of sodium chloride; the concentration of the salt solution is not less than 2%, preferably 2% to 35%, more preferably 10% to 20%.

[0090] Wherein, in step (3), the drug loading condition is to heat the organic phase solution and the aqueous phase solution to 35°C-42°C, preferably 38°C-42°C, and mix the three to load the drug.

[0091] The cooling in step (3) refers to cooling to below room temperature, preferably 0-20°C, more preferably 7-15°C.

[0092] Wherein, the concentrated solution in step (4) contains about 4-10 mg / ml of docetaxel, preferably 6-10 mg / ml, more preferably 7-9 mg / ml, and more preferably 8 mg / ml.

[0093] Wherein, step (4) dialyzes to remove excess small molecule compounds, and there is no particular restriction on the type and dosage of the dialysate and the molecular weight cutoff of the dialysis membrane, and those skilled in the art can make a choice based on common technical knowledge or experience. For the convenience of further preparation and clinical use, the dialysate is preferably an aqueous solution of a clinically acceptable osmotic pressure regulator, such as an aqueous solution of sodium chloride, glucose, phosphate or citrate. In some embodiments, sodium chloride solution is used as the dialysate for dialysis in step (4). The molecular weight cutoff of the dialysis membrane is 10-50KDa, preferably 10-30KDa, more preferably 10KDa or 30KDa. The volume of the dialysate is not less than 3 times that of the drug-carrying solution or the concentrated solution, preferably 3-10 times, and more preferably 3-6 times. The concentration of the sodium chloride solution is not higher than 1.8% (w / v), preferably 0.45%-1.8% (w / v), and more preferably 0.9%-1.8% (w / v).

[0094] In some embodiments, the human albumin solution used in step (2) needs to be adjusted in advance for the content of sodium octanoate. A person skilled in the art can select an appropriate method to adjust the content of sodium octanoate in the human albumin solution based on common technical knowledge or experience, including but not limited to dialysis.

[0095] In some embodiments, the method for adjusting the content of sodium octanoate in a human albumin solution is: taking a commercially available human albumin solution, diluting it with water for injection or normal saline to obtain a diluted albumin solution; dialyzing the diluted albumin solution with water for injection or normal saline as a dialysate to partially remove the sodium octanoate, thereby obtaining a human albumin solution with a low sodium octanoate content.

[0096] In some embodiments, the dilution multiple of the human albumin solution is not less than 4 times, preferably 4-7 times. For the dialysis, the molecular weight cutoff of the dialysis membrane is 10-50KDa, preferably 10-30KDa, more preferably 10KDa or 30KDa. The volume of the dialysate can be determined by a person skilled in the art according to the required sodium octanoate content through routine tests. Preferably, the volume of the dialysate is about 3 times or more of the volume of the diluted albumin solution, preferably 3-10 times, more preferably 3-6 times.

[0097] The human albumin solution with low sodium octanoate content contains sodium octanoate less than 0.16 mmol / g protein, preferably less than 0.12 mmol / g protein, preferably less than 0.10 mmol / g protein, preferably less than 0.08 mmol / g protein. The human albumin solution with low sodium octanoate content can be directly used to prepare the docetaxel albumin nanoparticle composition described in the present application, or can be mixed with other human albumin solutions with sodium octanoate content in proportion to obtain the desired content, and then used to prepare the docetaxel albumin nanoparticle composition.

[0098] In the preparation method, the dialysis step will remove excess small molecule compounds in the drug-carrying solution or the concentrated solution. For example, in some embodiments, step (2) uses acidic amino acids or acidic polypeptides to adjust the pH to prepare acid-denatured albumin; the dialysis step substantially removes excess acidic amino acids or acidic polypeptides; the composition contains almost no free acidic amino acids or acidic polypeptides. The "almost no free acidic amino acids or acidic polypeptides" means that the content of free acidic amino acids or acidic polypeptides in the composition is less than 0.25% (w / w) of docetaxel. For example, in some embodiments, cysteine ​​hydrochloride or glutathione is used to adjust the pH to prepare acid-denatured albumin, and the content of free cysteine ​​or glutathione in the composition is less than 0.25% (w / w) of docetaxel.

[0099] The relevant sequences of the present invention are as follows:

[0100] CDR-L1(Kabat)RASQDVNTAVA(SEQ ID NO:1)

[0101] CDR-L2(Kabat)SASFLYS(SEQ ID NO:2)

[0102] CDR-L3(Kabat)QQHYTTPPT(SEQ ID NO:3)

[0103] V L

[0104] DIQMTQSPSSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFL

[0105] YSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK

[0106] (SEQ ID NO:4)

[0107] LC

[0108] DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFL

[0109] YSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRT

[0110] VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQES

[0111] VTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0112] (SEQ ID NO:5)

[0113] CDR-H1-1(Kabat)DYTMD(SEQ ID NO:6)

[0114] CDR-H1-2(Kabat)DVNPNSGGSIYNQRFKG(SEQ ID NO:7)

[0115] CDR-H1-3(Kabat)NLGPSFYFDY(SEQ ID NO:8)

[0116] VH1

[0117] EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADV

[0118] NPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSF YFDYWGQGTLVTVSS(SEQ ID NO:9)

[0119] HC1

[0120] EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADV

[0121] NPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSF

[0122] YFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT

[0123] VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT

[0124] KVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV

[0125] VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDW

[0126] LNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLW

[0127] CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSALTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:10)

[0128] CDR-H2-1(Kabat)DTYIH(SEQ ID NO:11)

[0129] CDR-H2-2(Kabat)RIYPTNGYTRYADSVKG(SEQ ID NO:12)

[0130] CDR-H2-3(Kabat)WGGDGFYAMDY(SEQ ID NO:13)

[0131] VH2

[0132] EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIY

[0133] PTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS(SEQ ID NO:14)

[0134] HC2

[0135] EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIY

[0136] PTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGF

[0137] YAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP

[0138] VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS

[0139] NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTC

[0140] VVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ

[0141] DWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVS

[0142] LSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFKLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:15)

[0143] HC1’

[0144] EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVAD

[0145] VNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGP

[0146] SFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEP

[0147] VTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP

[0148] SNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT

[0149] CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLH

[0150] QDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQ

[0151] VSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:16)

[0152] HC2’

[0153] EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIY

[0154] PTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDG

[0155] FYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPE

[0156] PVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHK

[0157] PSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV

[0158] TCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVL

[0159] HQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKN

[0160] QVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO:17)

[0161] It should be understood that within the scope of this application, the above-mentioned technical features of this application and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0162] Attached Figure 1 : Schematic diagram of the structure of KN026. DETAILED DESCRIPTION

[0163] The following examples are provided to better illustrate the content of the present invention, but the content of the present invention is not limited to the examples. Those skilled in the art can make non-essential improvements and adjustments to the implementation scheme according to the above content of the invention, which still fall within the protection scope of the present invention.

[0164] Unless otherwise indicated, as used herein, the singular forms "a", "an" and "the" include the plural forms as well. For example, the term "a cell" includes a plurality of cells and mixtures thereof.

[0165] As used herein, the term "about" or "approximately" refers to the usual error range of each value that is readily known to those skilled in the art. The use of "about" or "approximately" values ​​or parameters herein includes (and describes) embodiments (or examples) involving the value or parameter itself.

[0166] As used herein, the term "comprising" or "including" means including the elements, integers or steps described, but does not exclude any other elements, integers or steps. In the present invention, when the term "comprising" or "including" is used, unless otherwise specified, the situation consisting of the elements, integers or steps described is also covered. For example, when referring to an antibody variable region "comprising" a specific sequence, it is also intended to cover the antibody variable region consisting of the specific sequence.

[0167] As used herein, the term "cancer" refers to a proliferative disorder caused by or characterized by the proliferation of cells that have lost susceptibility to normal growth control. The term "cancer" includes tumors and any other proliferative disorder. Cancers of the same tissue type originate from the same tissue and can be divided into different subtypes based on their biological characteristics.

[0168] As used herein, the term "treatment" refers to a clinical intervention intended to change the natural course of an individual or cell being treated during a clinical pathological process. The desired effects of treatment include delaying or reducing the rate of disease progression, improving or alleviating the disease state, and alleviating or improving prognosis. For example, if one or more symptoms associated with cancer are alleviated or eliminated, including but not limited to reducing the proliferation of cancer cells (or eliminating cancer cells), reducing symptoms caused by the disease, improving the quality of life of patients with the disease, reducing the dose of other drugs required to treat the disease, delaying the progression of the disease and / or prolonging the patient's survival, then the patient has been successfully "treated".

[0169] As used herein, the term "antibody" includes monoclonal antibodies (including full-length antibodies having an immunoglobulin Fc region), antibodies with multiple epitope specificities, multispecific antibodies (such as bispecific antibodies), dimers and single-chain antibodies, and antibody fragments (including antigen-binding fragments, such as Fab, F(ab')2 and Fv).

[0170] As used herein, the term "CDR (complementarity determining region)" refers to the amino acid sequence that together defines the binding affinity and specificity of the Fv region of an antibody. Because the specificity of an antibody lies in the structural complementarity between the antibody binding site and the antigenic determinant. The antibody binding site is composed of residues mainly from the so-called hypervariable region or complementary determining region (CDR). The light chain (L) and heavy chain (H) of an antibody each have three CDRs, and the antigen binding site of a conventional antibody includes six CDRs, which include a CDR set from each of the heavy chain variable region and the light chain variable region.

[0171] As used herein, the term "heavy chain variable region (VH)" refers to the amino-terminal variable region domain of an immunoglobulin heavy chain.

[0172] As used herein, the term "light chain variable region (VL)" refers to the amino-terminal variable region domain of an immunoglobulin light chain.

[0173] As used herein, the term "preparation unit" refers to the smallest sub-package of each pharmaceutical preparation containing an appropriate amount of active compound, such as a unit preparation in a capsule refers to a capsule, a unit preparation in a tablet refers to a tablet, a unit preparation in an injection refers to an injection, and so on for other types of preparations.

[0174] As used herein, the term "objective response rate (ORR)" is defined as the percentage of participants who achieved complete remission (CR) or partial remission (PR) during the study period using RECIST 1.1 criteria.

[0175] As used herein, the term "partial response" or "PR" means that compared with baseline, the sum of the diameters (SOD) of target lesions is reduced by at least 30%, there is no progression of non-target lesions, and no new lesions are generated, using the RECIST 1.1 standard.

[0176] As used herein, the term "complete response" or "CR" refers to the disappearance of all non-lymph node target lesions and non-target lesions without the generation of new lesions, using the RECIST 1.1 standard.

[0177] As used herein, the term "therapeutically effective amount" refers to an amount that brings a therapeutic effect to a subject, for example, in a subject to which this amount is administered, the symptoms or state of the disease are alleviated, reduced, or eliminated, or the development of the symptoms or state of the disease is delayed or inhibited, compared to a subject not administered this amount.

[0178] As used herein, the term "intolerance" means that the subject has previously received anticancer treatment but has experienced adverse event symptoms (such as peripheral neuropathy, skin toxicity, hyperglycemia, gastrointestinal symptoms) during the first two cycles, and despite following the dose adjustment guidelines, the symptoms have not improved, leading to treatment discontinuation, and there is no evidence of disease progression.

[0179] As used herein, the term "CnDm" represents the mth day of the nth dosing cycle, for example: C1D1 represents the first dosing time, and C4D1 represents the first day of the fourth dosing cycle.

[0180] As used herein, the term "recurrence" refers to the appearance of new lesions after cancer (eg, breast cancer) has been previously treated with radical treatment, representing the recurrence of cancer (eg, breast cancer).

[0181] As used herein, the term "metastasis" refers to the spread of tumor lesions beyond the primary site to the ipsilateral supraclavicular lymph nodes, ipsilateral internal mammary lymph nodes, ipsilateral axillary lymph nodes, ipsilateral chest wall, skin, etc., which is distant metastasis.

[0182] In some embodiments, the anti-HER2 antibody is composed of two different heavy chains (H) and two common light chains (L) with exactly the same sequence. The common light chain, each chain has three CDRs, respectively named CDR-L1, CDR-L2 and CDR-L3. In some embodiments, the common light chain comprises CDR-L1 as shown in SEQ ID NO: 1, CDR-L2 as shown in SEQ ID NO: 2 and CDR-L3 as shown in SEQ ID NO: 3. The heavy chain comprises heavy chain I targeting HER2 protein domain II and heavy chain II targeting HER2 protein domain IV. The heavy chain I has three CDRs, respectively named CDR-H1-1, CDR-H1-2 and CDR-H1-3. In some embodiments, the heavy chain I comprises CDR-H1-1 as shown in SEQ ID NO: 6, CDR-H1-2 as shown in SEQ ID NO: 7 and CDR-H1-3 as shown in SEQ ID NO: 8. The heavy chain II has three CDRs, which are named CDR-H2-1, CDR-H2-2 and CDR-H2-3. In some embodiments, the heavy chain II comprises CDR-H2-1 as shown in SEQ ID NO:11, CDR-H2-2 as shown in SEQ ID NO:12 and CDR-H2-3 as shown in SEQ ID NO:13.

[0183] In the present application, heavy chain I and heavy chain II are only used to distinguish two heavy chains targeting different epitopes, and have no meaning in terms of order or position.

[0184] The docetaxel albumin composition described in the present application is also referred to as docetaxel (albumin-bound). In some embodiments, the docetaxel albumin composition is a docetaxel albumin nanoparticle composition, which is prepared using a conventional method for preparing albumin nanoparticle drugs in the art. Since human albumin is an endogenous substance in the human body and has good biocompatibility, it can be used as a natural carrier for hydrophobic drugs, increase the solubility of poorly soluble drugs, and utilize the unique "gp60-caveolin-SPARC" channel of albumin to enrich the drug in the tumor area, thereby increasing the therapeutic effect.

[0185] In some embodiments, the docetaxel albumin composition described in the present application is prepared with reference to the method disclosed in WO2022184164A1, the entire disclosure of which is incorporated herein by reference.

[0186] In some embodiments, the anti-Her2 bispecific antibody disclosed in the present application is KN026. The sequences of the two common light chains of KN026 are both the amino acid sequence shown in SEQ ID NO:5, the sequence of the heavy chain I is the amino acid sequence shown in SEQ ID NO:10, and the sequence of the heavy chain II is the amino acid sequence shown in SEQ ID NO:15. The structure of KN026 is shown in the attached figure. Figure 1 The KN026 antibody can be prepared using conventional techniques in the art.

[0187] Fab1 (heavy chain I) of the KN026 antibody protein can specifically recognize domain II of the human HER2 protein and block the signal transduction of HER2 and other ERBB family members by forming heterodimers; Fab2 (heavy chain II) inhibits HER2-related signaling pathways by targeting domain IV of the human HER2 protein. The two inhibitory means work synergistically, enabling the KN026 bispecific antibody to more effectively inhibit the proliferation of HER2-positive tumor cells. In addition, the CH3 domains of the two heavy chains of KN026 contain a series of asymmetric amino acid mutations to increase the yield of heterodimeric antibody proteins while retaining complete Fc function. KN026 has obvious antibody-dependent cell-mediated cytotoxicity. The results of the in vitro anti-tumor cell proliferation experiment showed that the above-mentioned antibodies inhibited tumor cell proliferation in a dose-dependent manner. In some embodiments, the preparation of KN026 and related preparations disclosed in the present application can be prepared by conventional methods in the art, for example: the preparation can be a liquid preparation. For example, the preparation can be prepared in an aqueous carrier. For example, stabilizers may be added in an amount no greater than that which would result in a viscosity that is undesirable or unsuitable for intravenous administration. For example, the liquid formulation may further comprise one or more of a buffer, a surfactant, and a preservative.

[0188] Preparation Example

[0189] Docetaxel for injection (albumin-bound) used in the examples is produced by CSPC Pharmaceutical Group and prepared according to the method described in Prescription 1-1 of Example 1 of Patent WO2022184164A1. The details are as follows:

[0190] (1) Weigh 8 g of anhydrous docetaxel and dissolve it in 120 ml of ethanol to obtain an organic phase solution;

[0191] (2) Take a human albumin solution containing 36 g of albumin (the content of sodium octanoate is 0.08 mmol / g protein), dilute it with water for injection to a solution containing 15 mg / ml of albumin, then add an appropriate amount of cysteine ​​hydrochloride to adjust the pH to 4.1, incubate at 42°C for 30 min, and obtain an acid-denatured albumin aqueous phase solution; take 18 g of sodium chloride and prepare a saline solution with a concentration of 20% with water for injection;

[0192] (3) The organic phase solution and the aqueous phase solution were heated to 42°C, the organic phase, aqueous phase and salt solution were mixed to carry the drug, and the resulting material was placed in an ice water bath and cooled to 15°C to obtain a drug-loaded solution;

[0193] (4) Concentrating the drug-loaded solution to a docetaxel concentration of about 8 mg / ml to obtain a concentrated solution; using an isotonic sodium chloride solution (0.9%, w / v) as a dialysate to dialyze the concentrated solution 5 times, with a dialysis membrane molecular weight cutoff of 30 KDa, to obtain a dialyzed suspension; then, adding an appropriate amount of dialysate to adjust the concentration of the suspension to 4 mg / ml of docetaxel;

[0194] (5) sterilizing and filtering through a 0.45 μm + 0.2 μm membrane to obtain a suspension before lyophilization;

[0195] (6) taking the pre-lyophilized suspension obtained in step (5), lyophilizing to obtain a lyophilized powder.

[0196] KN026 comprises heavy chain I, heavy chain II and a common light chain, wherein the amino acid sequence of heavy chain I is shown in SEQ ID NO: 10, the amino acid sequence of heavy chain II is shown in SEQ ID NO: 15, and the amino acid sequence of the common light chain is shown in SEQ ID NO: 5.

[0197] The vector containing the nucleic acid sequence encoding the heavy chain I, heavy chain II and common light chain is transferred into cells, and KN026 is expressed and purified. The specific preparation process can be referred to patent application document WO2016110267.

[0198] Example 1: Clinical study

[0199] This is a randomized, controlled, open, multicenter, superiority phase III clinical study designed to compare the efficacy and safety of KN026 combined with docetaxel for injection (albumin-bound) versus trastuzumab combined with pertuzumab and docetaxel as first-line treatment for subjects with HER2-positive recurrent or metastatic breast cancer. 1. Research Methods

[0200] 1.1 Investigational drug information and dosing regimen:

[0201] (1) Investigational drug information

[0202]

[0203]

[0204] All the experimental drugs were provided by CSPC Pharmaceutical Group (Shanghai Jinman Biotechnology Co., Ltd.). (2) Dosage regimen for the experimental group

[0205] ①KN026

[0206] The drug is administered once every 3 weeks, on the first day of each cycle, with a dose of 30 mg / kg, and the first intravenous drip is 90 minutes (±15 minutes). If there is no infusion reaction, the infusion time of the subsequent cycle can be adjusted to 60 minutes (±15 minutes). Each bottle contains 325 mg (13 mL) of KN026 antibody. The required drug volume is calculated according to body weight, and the corresponding volume of drug is extracted and diluted to contain 250 mL of normal saline for intravenous drip.

[0207] ②Docetaxel for injection (albumin-bound)

[0208] The drug is given once every 3 weeks on the first day of each cycle at a dose of 100 mg / m 2 , intravenous drip for 60min (±10min).

[0209] Each bottle contains 80 mg of docetaxel (albumin-bound) powder for injection, which is dispersed and dissolved in 20 mL of water for injection to form a 4 mg / mL suspension. The corresponding volume of medication is calculated based on the subject's body surface area and injected into the infusion bag. At the same time, the same volume of physiological saline as the above medication volume is taken for dilution to prepare a solution with a concentration of 2 mg / mL for intravenous drip.

[0210] The order of drug administration in the experimental group was KN026 and docetaxel for injection (albumin-bound), and it was recommended to observe for at least 30 minutes between the administration of the two drugs.

[0211] To prevent severe blood toxicity, granulocyte colony-stimulating factor (G-CSF) can be used prophylactically, and docetaxel (albumin-bound) injection should be used 24 to 72 hours after the end of infusion.

[0212] (3) Dosage regimen for control group:

[0213] ①Pertuzumab injection

[0214] The drug is administered once every 3 weeks on the first day of each cycle. The starting dose is 840 mg, which is intravenously infused for 60 minutes (±10 minutes). The dose for each cycle thereafter is 420 mg, and the infusion time is 30 to 60 minutes (±10 minutes). Note: If the delay in administration results in an interval of ≥6 weeks between two consecutive infusions, a loading dose of 840 mg of Pertuzumab should be re-administered, followed by a dose of 420 mg once every 3 weeks.

[0215] Each vial contains 14 mL of concentrate at a concentration of 30 mg / mL. Calculate the appropriate volume of medication and add it to 250 mL of normal saline for intravenous drip. Note: Do not use 5% glucose solution to dilute Pertuzumab because its chemical and physical properties are unstable in 5% glucose solution.

[0216] ②Trastuzumab for injection

[0217] The drug is administered once every 3 weeks, on the first day of each cycle, with an initial dose of 8 mg / kg, intravenous infusion for 90 minutes (±10 minutes); the dose for each cycle thereafter is 6 mg / kg, intravenous infusion for 30 to 90 minutes (±10 minutes). If delayed administration results in an interval of ≥6 weeks between two consecutive infusions, trastuzumab 8 mg / kg loading dose should be re-administered, followed by continued administration at a dose of 6 mg / kg once every 3 weeks.

[0218] The corresponding medication volume was calculated according to the subject's body weight and added to 250 mL of normal saline for intravenous drip.

[0219] ③Docetaxel injection

[0220] The drug is given once every 3 weeks on the first day of each cycle at a dose of 75 mg / m 2 Each infusion should be no less than 60 minutes.

[0221] Before docetaxel injection is administered, pretreatment treatment is required according to the instructions [oral glucocorticoids, such as dexamethasone, 16 mg per day (e.g., 8 mg twice a day) for 3 days one day before docetaxel injection] or clinical routine practice.

[0222] The order of drug administration in the control group was pertuzumab, trastuzumab, and docetaxel, and at least 30 minutes of observation was recommended between each drug administration.

[0223] (4) Dosage adjustment

[0224] Dose reductions of KN026, trastuzumab, and pertuzumab were not permitted in this study. Dose reductions were permitted when adverse events related to treatment with docetaxel injection (albumin-bound) or docetaxel injection occurred. A maximum of two dose reductions were permitted for docetaxel injection (albumin-bound), and if a third dose reduction was required, the drug must be permanently discontinued. Only one dose reduction was permitted for docetaxel injection, and if a second dose reduction was required, the drug must be permanently discontinued.

[0225] Docetaxel for injection (albumin-bound) Docetaxel Injection Initial dose <![CDATA[100mg / m 2 ]]> <![CDATA[75mg / m 2 ]]> First reduction <![CDATA[75mg / m 2 ]]> <![CDATA[60mg / m 2 ]]> Second reduction <![CDATA[60mg / m 2 ]]> not applicable

[0226] 1.2 Inclusion and Exclusion Criteria

[0227] Inclusion Criteria

[0228] Subjects must meet all of the following inclusion criteria to be enrolled in this study:

[0229] 1) Voluntarily participate in this study and sign the informed consent form (ICF);

[0230] 2) Aged ≥18 years;

[0231] 3) Recurrent or metastatic breast cancer confirmed by histology and / or cytology;

[0232] 4) The latest tumor tissue sample was confirmed to be HER2 positive (IHC3+, or IHC2+ and ISH positive) by central laboratory testing;

[0233] 5) Subjects who have not received systemic chemotherapy and / or HER2-targeted therapy for recurrent or metastatic breast cancer (subjects who have received one endocrine therapy regimen are allowed to be included in the group); subjects who relapse more than 12 months after the completion of (neo)adjuvant chemotherapy or HER2-targeted therapy can be considered for inclusion;

[0234] 6) Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;

[0235] 7) There is at least one measurable or evaluable lesion (RECIST 1.1);

[0236] 8) Have adequate organ and bone marrow function (no blood transfusion within 14 days before the test, no use of hematopoietic stimulating factor drugs to correct the state):

[0237] a) Neutrophil count ≥ 1.5 × 10 9 / L;

[0238] b) Platelet count ≥100×10 9 / L;

[0239] c) Hemoglobin ≥90 g / L;

[0240] d) Liver function: total bilirubin (TBIL) ≤ 1.0 × upper limit of reference value (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (≤ 5 × ULN for subjects with liver metastasis);

[0241] e) Renal function: creatinine clearance ≥ 30 mL / min (calculated using the Cockcroft-Gault formula);

[0242] f) Coagulation function: international normalized ratio (INR) ≤ 1.5, and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN (for subjects receiving anticoagulant therapy, the investigator judged that both INR and APTT were within the safe and effective therapeutic range);

[0243] g) left ventricular ejection fraction (LVEF)>50%;

[0244] 9) Expected survival time ≥ 3 months;

[0245] 10) Female subjects of childbearing age must undergo a blood pregnancy test within 7 days before randomization, with a negative result, and agree to use reliable and effective contraception methods during the study treatment and within 3 months (docetaxel injection and docetaxel injection (albumin-bound)) or within 7 months (trastuzumab, pertuzumab and KN026) after the last study treatment (whichever is the longest). Male subjects whose partners are women of childbearing age must agree to use reliable and effective contraception methods during the study treatment and within 3 months (docetaxel injection and docetaxel injection (albumin-bound)) or within 7 months (trastuzumab, pertuzumab and KN026) after the last study treatment (whichever is the longest).

[0246] Exclusion criteria

[0247] Subjects who meet any of the following criteria will not be allowed to enter this study:

[0248] 1) Patients with contraindications to trastuzumab, pertuzumab, and docetaxel or who are deemed unsuitable for KN026 or docetaxel for injection (albumin-bound) by the investigator;

[0249] 2) ALT and / or AST>1.5×ULN and alkaline phosphatase (ALP)>2.5×ULN;

[0250] 3) Subjects with grade ≥3 peripheral neuropathy at the time of randomization;

[0251] 4) The toxicity of previous anti-tumor treatment has not recovered to the Common Terminology Criteria for Adverse Events (CTCAE 5.0) ≤ Grade 1 (except for toxicities such as alopecia, peripheral neuropathy, and simple laboratory tests that the investigators judge to have no safety risks, which need to be alleviated to ≤ Grade 2);

[0252] 5) Patients whose LVEF has dropped to <50% during previous anti-HER2 drug treatment, or who have developed symptomatic congestive heart failure (CHF), or who have experienced toxicity leading to permanent discontinuation of treatment;

[0253] 6) Those with known allergies and / or contraindications to glucocorticoids (including but not limited to active peptic ulcer, severe hypertension, severe hypokalemia, glaucoma, etc.);

[0254] 7) Patients who have received anthracycline therapy in the past and the cumulative dose has reached the following: doxorubicin or liposomal doxorubicin> 360 mg / m 2 ; Epirubicin>720mg / m 2 ; Mitoxantrone>120mg / m 2 ; Other anthracyclines > equivalent to 360 mg / m 2If more than one anthracycline is used, the cumulative dose should not exceed the equivalent of 360 mg / m 2 of doxorubicin;

[0255] 8) Use of strong CYP3A4 inhibitors within 14 days before randomization;

[0256] 9) Contraindications or history of hypersensitivity to any of the study drug ingredients or any known excipients;

[0257] 10) Untreated or unstable brain metastasis, spinal cord metastasis or compression, carcinomatous meningitis; subjects who have received local brain treatment and have stable symptoms, imaging examinations show stability for at least 4 weeks before randomization, no evidence of brain edema, and do not require glucocorticoid treatment can be considered for inclusion;

[0258] 11) Active malignant tumors within 3 years before randomization, excluding breast cancer studied in this trial and any locally curable tumor that has received radical treatment (such as resected basal cell or squamous cell skin cancer, superficial bladder cancer, cervical or breast carcinoma in situ, early thyroid cancer, etc.);

[0259] 12) With uncontrolled or serious cardiovascular and cerebrovascular diseases, including but not limited to:

[0260] a) Congestive heart failure of New York Heart Association (NYHA) grade II or above, unstable angina, myocardial infarction, or arrhythmia causing hemodynamic instability within 6 months before randomization;

[0261] b) Primary cardiomyopathy (such as dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, unspecified cardiomyopathy);

[0262] c) History of clinically significant QT interval prolongation, or QTcF (calculated using Fridericia formula) > 450ms during the screening period;

[0263] d) Arterial / venous thrombotic events occurred within 6 months before randomization, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism;

[0264] e) uncontrolled hypertension (systolic blood pressure > 160 mmHg and / or diastolic blood pressure > 100 mmHg);

[0265] 13) Severe chronic or active infection (including tuberculosis infection, etc.) requiring systemic antibacterial, antifungal or antiviral treatment within 14 days before randomization;

[0266] 14) Active hepatitis B (HBsAg positive and HBV-DNA ≥ 2×10 3 IU / mL) or hepatitis C (positive hepatitis C antibody and HCV-RNA quantitative test result > lower limit of detection range); Note: For the lower limit of detection range < HBV DNA < 2×10 3 Hepatitis B virus carriers with a HBV infection rate of ≥10 IU / mL and who are willing to take entecavir or other antiviral treatments based on clinical judgment during the study period may be considered for inclusion;

[0267] 15) Those with a known history of human immunodeficiency virus (HIV) infection;

[0268] 16) Those who are currently participating in other clinical studies (except non-interventional clinical studies or those in the follow-up period of interventional studies) or whose time from the end of the previous clinical study (last medication) to the end of randomization is less than 4 weeks;

[0269] 17) Patients who had received anti-tumor treatments such as radiotherapy, targeted therapy, immunotherapy, and other clinical research drugs within 28 days before randomization, or had used traditional Chinese medicine with anti-tumor indications within 14 days;

[0270] 18) Within 7 days before randomization, there is uncontrollable serous cavity effusion (such as pleural effusion, peritoneal effusion, pericardial effusion, etc.) that requires frequent drainage or medical intervention, or additional intervention is required within 2 weeks after the intervention (excluding exfoliative cytology testing of exudate);

[0271] 19) Underwent major organ surgery (excluding puncture biopsy) within 28 days before randomization;

[0272] 20) Pregnant or lactating women;

[0273] 21) There are other circumstances that may interfere with the subject's participation in the research procedures or are inconsistent with the subject's maximum benefit from participating in the research or affect the research results: such as a history of mental illness, drug abuse, or any other clinically significant disease or condition.

[0274] 1.3 Evaluation Metrics

[0275] 1.3.1 Efficacy evaluation

[0276] The imaging efficacy was evaluated using RECIST 1.1. The efficacy evaluation indicators included:

[0277] ORR: the proportion of subjects with CR and PR to all subjects (assessed by BIRC and investigators);

[0278] (PR: Compared with the baseline sum of target lesion diameters, the sum of target lesion diameters decreased by ≥30%, and non-target lesions did not progress and no new lesions occurred.

[0279] CR: refers to the disappearance of all non-lymph node target lesions and non-target lesions, and no new lesions are generated)

[0280] Regular safety assessments were performed throughout the study, including physical examination, vital signs, weight, 12-lead electrocardiogram, echocardiogram, and laboratory tests. The severity of adverse events was recorded using the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (NCI-CTCAE 5.0).

[0281] 2. Research Results

[0282] (1) The results of efficacy evaluation are as follows:

[0283] As of February 2024, a total of 267 subjects were enrolled, of which 170 had post-baseline efficacy evaluations, including 85 in the experimental group and 85 in the control group (trastuzumab + pertuzumab + docetaxel). Among the 85 cases in the experimental group, 67 had PR, with an ORR of 78.8%. Among the 85 cases in the control group, 56 had PR, with an ORR of 65.9%. The PR and ORR values ​​of the experimental group were significantly higher than those of the control group, indicating that the interim ORR data of the experimental group of this application achieved a better anti-tumor efficacy trend than that of the control group.

[0284] (2) The safety assessment results are as follows:

[0285] So far, no new adverse reaction signals have been found in the trial group of this application.

[0286] The combination of anti-HER2 antibody (KN026) and docetaxel albumin for the treatment of HER2-positive recurrent metastatic breast cancer has better anti-tumor efficacy than the existing standard treatment regimen, with good overall safety and more convenient administration. It can provide such patients with a first-line treatment option with better efficacy, good safety and more convenient treatment.

Claims

1. Use of an anti-HER2 antibody and a second therapeutic agent in the preparation of a medicament for treating cancer, wherein the second therapeutic agent is a docetaxel albumin composition.

2. Use of an anti-HER2 antibody in the preparation of a medicament for enhancing the efficacy of a second therapeutic agent in treating cancer, wherein the second therapeutic agent is a docetaxel albumin composition.

3. A method for treating cancer using an anti-HER2 antibody and a second therapeutic agent, wherein the second therapeutic agent is a docetaxel albumin composition.

4. A pharmaceutical composition or a kit or a medicine box for treating cancer, comprising an anti-HER2 antibody and a second therapeutic agent, wherein the second therapeutic agent is a docetaxel albumin composition.

5. The use, method, pharmaceutical composition, kit or drug box according to any one of claims 1 to 4, wherein the anti-HER2 antibody is an anti-HER2 bispecific antibody; preferably, the anti-HER2 antibody is a bispecific antibody targeting different epitopes of human HER2 protein; more preferably, the different epitopes of HER2 protein are domain II and domain IV thereof.

6. The use, method, pharmaceutical composition, kit or drug kit according to any one of claims 1 to 5, wherein the anti-HER2 antibody comprises two common light chains with identical sequences; preferably, the common light chain comprises CDR-L1 as shown in SEQ ID NO: 1, CDR-L2 as shown in SEQ ID NO: 2 and CDR-L3 as shown in SEQ ID NO: 3; more preferably, the common light chain comprises a light chain variable region as shown in SEQ ID NO: 4; further preferably, the common light chain comprises an amino acid sequence as shown in SEQ ID NO:

5.

7. The use, method, pharmaceutical composition, kit or drug box according to any one of claims 1 to 6, wherein the anti-HER2 antibody comprises two heavy chains with different sequences; preferably, the heavy chain comprises heavy chain I targeting HER2 protein domain II, and / or heavy chain II targeting HER2 protein domain IV.

8. The use, method, pharmaceutical composition, kit or drug kit according to claim 7, wherein the heavy chain I comprises CDR-H1-1 as shown in SEQ ID NO: 6, CDR-H1-2 as shown in SEQ ID NO: 7 and CDR-H1-3 as shown in SEQ ID NO: 8; preferably, the heavy chain I comprises the heavy chain I variable region as shown in SEQ ID NO: 9; more preferably, the heavy chain I comprises the amino acid sequence as shown in SEQ ID NO: 10 or SEQ ID NO: 16; and / or, The heavy chain II comprises CDR-H2-1 as shown in SEQ ID NO:11, CDR-H2-2 as shown in SEQ ID NO:12 and CDR-H2-3 as shown in SEQ ID NO:13; preferably, the heavy chain II comprises the heavy chain II variable region as shown in SEQ ID NO:14; more preferably, the heavy chain II comprises the amino acid sequence as shown in SEQ ID NO:15 or SEQ ID NO:

17.

9. The use, method, pharmaceutical composition, kit or medicine box according to any one of claims 1 to 8, wherein the docetaxel albumin composition comprises docetaxel and acid-denatured albumin; preferably, the docetaxel is selected from anhydrous docetaxel; more preferably, the weight ratio of the docetaxel to the albumin is 1:(4.0-6.0).

10. The use, method, pharmaceutical composition, kit or drug box according to claim 9, wherein the acid-denatured albumin is obtained by denaturing human serum albumin by adding acid to an appropriate pH value; preferably, the acid is cysteine ​​hydrochloride; preferably, the pH value is about 4.

1.

11. The use, method, pharmaceutical composition, kit or drug box according to any one of claims 1 to 10, wherein the docetaxel albumin composition further comprises an osmotic pressure regulator, sodium octanoate; preferably, the osmotic pressure regulator is sodium chloride; more preferably, the weight ratio of the sodium chloride to the docetaxel is about 2.25:1; preferably, the sodium octanoate content is less than 0.16 mmol / g protein; more preferably, the sodium octanoate content is less than 0.08 mmol / g protein.

12. The use, method, pharmaceutical composition, kit or drug kit according to any one of claims 1 to 11, wherein the cancer includes but is not limited to a hematological tumor or a solid tumor.

13. The use, method, pharmaceutical composition or kit or medicine box of claim 12, wherein the blood tumor is a lymphoma or leukemia, including but not limited to myeloma, B-cell lymphoma, mantle cell lymphoma, non-Hodgkin's B-cell lymphoma, non-Hodgkin's T-cell lymphoma, cutaneous lymphoma, anaplastic large cell lymphoma, multiple myeloma, indolent non-Hodgkin's lymphoma, plasmacytoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, follicular lymphoma; the solid tumor includes but is not limited to bladder cancer, brain cancer, breast cancer, cervical cancer, chest tumor, endometrial cancer, esophageal squamous cell carcinoma, gastric cancer, head tumor, pancreatic cancer, bile duct cancer, colorectal cancer, eye cancer, head and neck squamous cell carcinoma, urothelial carcinoma, kidney cancer, liver cancer, lymph node cancer, lung cancer, oral cancer, neck tumor, ovarian cancer, prostate cancer, testicular cancer, laryngeal cancer and uterine cancer, melanoma, skin cancer, salivary gland cancer, soft tissue sarcoma and osteosarcoma.

14. The use, method, pharmaceutical composition, kit or drug box according to claim 12, wherein the solid tumor is breast cancer; preferably, the breast cancer is HER2-positive breast cancer; more preferably, the breast cancer is HER2-positive recurrent and / or metastatic breast cancer.

15. The use, method, pharmaceutical composition, kit or drug kit according to any one of claims 1 to 14, wherein the anti-HER2 antibody and the second therapeutic agent are contained in the same preparation unit, or are respectively contained in separate preparation units.

16. The use, method, pharmaceutical composition, kit or medicine box according to any one of claims 1 to 15, wherein the docetaxel albumin composition is formulated into a preparation, and each preparation unit contains 50-100 mg of docetaxel (calculated as anhydrous docetaxel), preferably 70-90 mg, and more preferably about 80 mg; and / or, the anti-HER2 antibody is formulated into a preparation, and the content of the anti-HER2 antibody or a pharmaceutically acceptable form thereof (calculated as anhydrous anti-HER2 antibody) in each preparation unit is in the range of about 0.01 mg to about 400 mg, preferably 300-400 mg, more preferably about 300 mg, about 325 mg, about 350 mg, about 375 mg, or about 400 mg.

17. The use, method, pharmaceutical composition, kit or drug kit according to any one of claims 1 to 16, wherein the docetaxel albumin composition is administered at a dose of 60-125 mg / m 2 , preferably 60-100 mg / m 2 , more preferably about 60 mg / m 2 , about 75mg / m 2 or about 100 mg / m 2 ; and / or, the anti-HER2 antibody is administered at a dose of: 0.01 mg / kg-100 mg / kg, preferably 20-40 mg / kg, 20 mg / kg-30 mg / kg, 25 mg / kg-35 mg / kg, more preferably about 30 mg / kg.

Citation Information

Cited By

  • Use of docetaxel-albumin composition in treatment of gastric cancer or gastroesophageal junction cancer

    WO2025232873A1